Rheumatology - Update 2021 - Edyta Biernat-Kaluza, MD, PhD (2021 Conference) (LDN, low dose naltrexone)

Reclaim the Lives of Lupus Patients, A Unique Treatment Approach - Deanna Windham, DO (2021 Conference) (LDN, low dose naltrexone)

PTSD and other mental health treatment with opioid antagonist... - Galyn Forster, MS, LPC (2021 Conference) (LDN, low dose naltrexone)

New approaches to managing fibromyalgia pain - Ginevra Liptan, MD (2021 Conference) (LDN, low dose naltrexone)

Multiple Sclerosis - The role of combination therapy of LDN and Testosterone ... - Harpal Bains, MD (2021 Conference) (LDN, low dose naltrexone)

Lyme Disease - Darin Ingels, ND (2021 Conference) (LDN, low dose naltrexone)

Henoch-Schonlein Purpura - Sally Daughtrey, ND (2021 Conference) (LDN, low dose naltrexone)

In her presentation, Dr. Daughtry explains Henoch-Schonlein (HSP), its triggers and complications (such as serious hidden infections often missed initially), and the use of Low Dose Naltrexone in treating HSP. Dr. Daughtry gives an in-depth look into one pediatric case she treated successfully with LDN.

Eosinophilic Esophagitis Is More Treatable Than You Think - Deanna Windham, DO (2021 Conference) (LDN, low dose naltrexone)

Endogenous opioids modulate inflammation in the animal model of Multiple Sclerosis - Chirag Patel, MD (2021 Conference) (LDN, low dose naltrexone)

Delivery Systems - Yusuf Saleeby, MD (2021 Conference) (LDN, low dose naltrexone)

In this presentation, Dr. Saleeby discusses different delivery systems for Naltrexone/LDN and ultra low dose Naltrexone, the nuances for the different types of delivery systems, and how to best write a professional compounding prescription.